Alerta

COMPUTER-IMPLEMENTED METHODS FOR PREDICTING GLUCOSE VALUES, DATA PROCESSING SYSTEM, MEDICAL SERVER, AND USER DEVICE

Resumen de: US20260013801A1

Methods for predicting glucose values which involve determining a predicction time window using historical data indicative of glucose level influencing events of a person having diabetes and at least one predicted glucose level influencing event. Further disclosed are data processing systems for predicting glucose values, medical servers, user devices, and computer programs.

MULTI-PARAMETER DIABETIC FOOT MONITORING SYSTEM WITH INTEGRATED COMMUNICATION PROTOCOLS

Resumen de: US20260013793A1

A multi-modal sensor system for monitoring a user includes a smart sock and smart insole configured to be worn on a foot of the use. The sock and insole each have a multi-modal sensor array integrated within their respective structures. For example, the sensor array may include a temperature sensor, a pressure sensor, a moisture sensor, and an optical sensor to measure multiple physiological parameters on the foot of the user. Processing electronics provide for early detection of inflammation, pressure ulceration risk, and circulation changes through coordinated wireless communication between the sock and insole for comprehensive diabetic foot health monitoring during continuous daily wear applications.

PREDICTIVE LONG HYPERGLYCEMIA ALERTS

Resumen de: AU2024306140A1

Improved alarms for analyte monitoring systems are provided. For example, disclosed herein are various embodiments of methods, systems, and interfaces for long hyperglycemic alerts or pre-alerts. In addition, various embodiments of methods, systems, and interfaces for modified high glucose alerts, which predict if the high glucose episode is associated with a recently administered medication dose are described. Also, systems that include both high glucose alerts and long hyperglycemic alert options are described, in addition to enabling and disabling or suppressing certain alerts under various conditions.

DETECTION OF ANOMALOUS COMPUTING ENVIRONMENT BEHAVIOR USING GLUCOSE

Resumen de: US20260018305A1

Detection of anomalous computing environment behavior using glucose is described. An anomaly detection system receives glucose measurements and event records during a first time period. Missing events that are missing from the event records during the first time period are identified by processing the glucose measurements using an event engine simulator. An anomaly detection model is generated based on the missing events during the first time period. Subsequently, the anomaly detection system receives additional glucose measurements and additional event records during a second time period. Missing events that are missing from the additional event records during the second time period are identified by processing the additional glucose measurements using the event engine simulator. Anomalous behavior is detected if the identified missing events that are missing from the event records during the second time period are outside a predicted range of missing events of the anomaly detection model.

AI-BASED METHODS AND SYSTEMS FOR PREDICTING DIABETES RISK AND RELATED METABOLIC PARAMETERS

Resumen de: US20260018302A1

Present disclosure describes techniques for predicting diabetes risk in patients. The techniques include the step of monitoring a plurality of patient-specific characteristics comprising, at least one physiological parameter, one behavioral indicator, and one visual representation of the patient. The method further comprises extracting, using a first artificial intelligence (AI) model, a stress level of the patient based at least on behavioral indicators, historical lifestyle data, and sensor-derived physiological parameters. The method then include extracting, using a second AI model, a body mass index (BMI) or fat distribution patterns based at least on silhouette images and weight of the patient. The method finally includes predicting, using a third AI model, a blood sugar level or diabetes risk score of the patient based on outputs from the first and second AI models and the monitored characteristics.

SYSTEM AND DEVICE OF DYNAMIC GLUCOSE PROFILE RESPONSE TO PHYSIOLOGICAL PARAMETERS

Resumen de: AU2025259998A1

Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. ov o v

MEAL RESPONSE PREDICTION

Resumen de: US20260014318A1

A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, and predicting a future blood glucose level of the person at a first time after the time window using the physiological model and the meal-specific values of the parameters of the physiological model. In one example, an alert or a notification can be sent to a user or an electronic device based on the predicted future blood glucose level of the person.

METHOD OF DISPLAYING COMMUNICATION STATUS IN GLUCOSE MONITORING SYSTEM

Resumen de: AU2025203869A1

One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off. One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off. ay a y m o d u l e t u r n - o f f Start Display communication status S1201 Detect turn-off of communication module S1203 Delay display of communication module turn-off for one period of time S1205 If communication module turn-off persists for one period of time, S1207 modify display of communication status Display communication module turn-off S1209 End ay a y

INFUSION DEVICE FOR CONTINUOUS GLUCOSE MONITORING

Resumen de: AU2025275314A1

Abstract The present disclosure provides systems and devices for combining analyte monitoring with fluid delivery, including devices that are adapted for use with combined sensors and cannulas having sensors and cannulas on a single component. These systems and devices may be used in various applications with simultaneous in vivo monitoring of analyte concentrations and delivery of medications. The systems and devices use a combined sensor and cannula attached to a body that provides electrical coupling of the sensor to a signal processing device and fluidic coupling of the cannula to a medication delivery source, in order to combine subcutaneous liquid medication delivery and amperometric analyte sensing without a need for multiple skin piercing elements.

METHODS TO RAPIDLY ASSESS CHANGES IN MEDICAMENT NEEDS FOR ACCELERATED SHORT-TERM ADAPTIVITY OF AUTOMATED MEDICAMENT DELIVERY SYSTEMS

Resumen de: EP4679441A1

Exemplary embodiments relate to automated medicament delivery (AMD) devices. Exemplary methods and apparatuses allow the AMD to account for the eventual impact of remaining medicament-on-board (MOB) on reduction in glucose concentrations, and do not incorporate the impact of meals on increases in glucose concentrations. This allows the AMD system to estimate the user's final glucose concentration if the impact of both carbohydrate ingestion and existing MOB are fully realized. Consequently, an AMD system can personalize its behaviors to a particular user more rapidly than if the system were to rely simply on previous medicament delivery and glucose histories. This is especially useful when a user begins using an AMD system with an inaccurate or poorly estimated initial value for total daily medicament (TDM) delivery.

MEAL RESPONSE PREDICTION

Resumen de: EP4679440A1

A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, and predicting a future blood glucose level of the person at a first time after the time window using the physiological model and the meal-specific values of the parameters of the physiological model. In one example, an alert or a notification can be sent to a user or an electronic device based on the predicted future blood glucose level of the person.

RESIDUAL CARB ESTIMATION FOR BOLUS CALCULATION

Resumen de: EP4679439A1

A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, estimating an amount of residual glucose or residual carbohydrate of the meal that would not be counteracted by insulin already delivered to the person using the physiological model and the meal-specific values of the parameters of the physiological model, and determining a dose of a correction bolus to be delivered to the person based on the amount of residual glucose or residual carbohydrate of the meal.

A raman probe and apparatus and method for non-invasive in vivo measurement of analyte presence or concentration

Resumen de: GB2700315A

A non-invasive in vivo measurement by Raman spectroscopy of an analyte (e.g. glucose) present in the skin of a subject (e.g. in the interstitial fluid). A controllable vertical-cavity surface-emitting laser (VCSEL) source 32, spatially separated from a detector 30, irradiates the skin 33 of the subject. The VSCELs selectively change the wavelength of light in using SWEPT methodologies. A bandpass filter receives Raman scattered radiation transmitted from the sample and a processor generates a Raman spectrum from the received Raman scattered radiation. The VCSELs may be distributed around the detector. The light sources 151 may be included in a generally planar probe (e.g. provided on a PCB) integrated with a spectrometer for miniaturisation. The probe may include a slit plate 146 having a slit 148 around which the light sources are arranged. The arrangement may provide spatially offset Raman spectroscopy (SORS). Figs 3&19A

CONTINUOUS BLOOD SUGAR MEASURING SENSOR MEMBER

Resumen de: EP4678094A2

The present disclosure relates to a continuous blood sugar measuring sensor member, wherein: since an electrode layer formed on one surface of a substrate is connected to a sensor contact point part on the other surface of the substrate through a via hole and thus two electrode layers may be formed on different opposite surfaces without having to be formed on the same surface of the substrate, the width of the substrate may be further reduced and an overall minimized and simplified structure may be ensured; since an electrode connection layer formed at the via hole is not formed in a shape of filling the via hole but is formed only on the inner circumferential surface, a filling defect occurring in a process of filling the via hole and a fault in electrical connection according thereto may be prevented and thus a more stable structure may be ensured; and since a plurality of via holes are formed, despite damage to or the occurrence of a defect in an electrode connection layer formed at one of the via holes, electrical connection is maintained by electrode connection layers formed at the remaining via holes, and thus more stable performance may be maintained.

CONTINUOUS ANALYTE MONITORING SYSTEM WITH MICRONEEDLE ARRAY

Resumen de: AU2025271165A1

Abstract Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable. WO 2022/026764 PCT/US2021/043786 160 110 FIG. 1 Additional 128Sensor(s) Sensor Microneedle\ Controller(s) Comm. Array Circuitry Module(s) 140 124 126 a Power Circuitry Source(s) ov o v e n s o r i c r o n e e d l e \ o m m o w e r

DISAGGREGATION OF FACTORS AFFECTING BLOOD GLUCOSE LEVEL

Resumen de: WO2026008380A1

In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time. The present invention further contemplates the extraction of one or more features of the blood glucose signal received from the one or more sensors. Using this information, a relative non-digestion- related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion- related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.

ESTIMATION OF DIABETES RISK BASED ON BIOMARKERS

Resumen de: WO2026008382A1

In an approach to estimating diabetes risk, the present invention receives a biomarker signal over a first period of time. From the biomarker signal, the presently claimed invention extracts one or more features of the biomarker signal and determines a first trend associated with insulin resistance based on the one or more features of the biomarker signal. Using this information, the present invention can determine a relative non-digestion-related contribution to the blood glucose signal and/or a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion- related contribution is determined from the relative digestion-related and non-digestion-related contribution.

DETERMINATION OF STRESS-RELATED CONTRIBUTIONS TO BLOOD GLUCOSE LEVEL

Resumen de: WO2026008357A1

In an approach to determining stress contributions to blood glucose levels, the present invention receives a blood glucose signal over a first period of time and a biomarker signal over a second period of time. The present invention extracts one or more blood glucose level signal features from the blood glucose signal, one or more biomarker signal features from the biomarker signal to determine a blood glucose level of time-based stress contribution and a biomarker-based stress contribution.

GLUCOSE SENSOR APPARATUS ADDRESSING INTERFERENCE OF ASCORBIC ACID AND ACETAMINOPHEN

Resumen de: US20260007341A1

This disclosure relates to an apparatus for glucose-sensing that address interference of ascorbic acid and acetaminophen. The apparatus includes a first electrode capable of oxidizing glucose and at least one of ascorbic acid and acetaminophen. The apparatus further includes a second electrode capable of oxidizing at least one of ascorbic acid and acetaminophen but not capable of oxidizing glucose. The first electrode includes a deposit of irregularly shaped bodies that are formed of numerous nanoparticles having a generally oval or spherical shape with a length ranging between about 2 nm and about 5 nm.

SYSTEMS, METHODS, AND DEVICES FOR BIOPHYSICAL MODELING AND RESPONSE PREDICTION

Resumen de: US20260007336A1

Various systems and methods are disclosed. One or more of the methods disclosed uses machine learning algorithms to predict biophysical responses from biophysical data, such as heart rate monitor data, food logs, or glucose measurements. Biophysical responses may include behavioral responses. Additional systems and methods extract nutritional information from food items by parsing strings containing names of food items.

THERMAL IMAGING SYSTEM FOR DETECTION OF EARLY STAGES OF DIABETIC FOOT ULCERS

Resumen de: US20260007359A1

A thermal imaging system for detection of diabetic foot ulcers including a mobile device having a graphical user interface. The thermal imaging system includes a thermal camera in communication with the mobile device for obtaining thermal images of patient feet and sending the thermal images to the mobile device. The thermal imaging system includes an application on the mobile device having instruction for analyzing the thermal images using a temperature condition index during analysis. The application provides data results on the interactive dashboard of the graphical user interface. The instruction for analyzing the thermal images include AI-driven analysis for delivering rapid results, reducing need for extensive medical expertise. Following analysis, the application generates a detailed report including information on categorization of the diabetic foot condition, risk level, recommended screening frequency and suggested actions.

METHOD, SYSTEM AND COMPUTER READABLE MEDIUM FOR ASSESSING ACTIONABLE GLYCEMIC RISK

Resumen de: US20260007370A1

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.

APPARATUS AND METHOD FOR NON-INVASIVE BLOOD GLUCOSE MONITORING

Resumen de: US20260007335A1

The present invention relates to apparatus for non-invasive blood glucose monitoring, which includes: a signal transmitting module that transmits a terahertz wireless signal modulated into a PRBS pattern at a terahertz carrier frequency to a body part; a signal receiving module that demodulates the terahertz wireless signal reflected from the body part to measure performance parameters of the modulation pattern; and a sensing module that performs multivariate analysis using the performance parameters of the modulation pattern measured through the signal receiving module and quantifies features related to blood glucose through the multivariate analysis to measure blood glucose concentration.

METHODS TO RAPIDLY ASSESS CHANGES IN MEDICAMENT NEEDS FOR ACCELERATED SHORT-TERM ADAPTIVITY OF AUTOMATED MEDICAMENT DELIVERY SYSTEMS

Resumen de: US20260007824A1

Exemplary embodiments relate to automated medicament delivery (AMD) devices. Exemplary methods and apparatuses allow the AMD to account for the eventual impact of remaining medicament-on-board (MOB) on reduction in glucose concentrations, and do not incorporate the impact of meals on increases in glucose concentrations. This allows the AMD system to estimate the user's final glucose concentration if the impact of both carbohydrate ingestion and existing MOB are fully realized. Consequently, an AMD system can personalize its behaviors to a particular user more rapidly than if the system were to rely simply on previous medicament delivery and glucose histories. This is especially useful when a user begins using an AMD system with an inaccurate or poorly estimated initial value for total daily medicament (TDM) delivery.

BLOOD GLUCOSE LEVEL SENSING DEVICE

Nº publicación: WO2026008858A1 08/01/2026

Solicitante:

THE UNIV COURT OF THE UNIV OF GLASGOW [GB]
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW